Epidemiology and impact of nosocomial infections;Epidemiología e impacto de las infecciones nosocomiales

Medicina Intensiva

Volumn 34, Issue 4, 2010, Pages 256-267

  Olaechea, P M ^a   Insausti, J ^b   Blanco, A ^c   Luque, P ^d  

^a HOSPITAL DE GALDAKAO   (Spain)

^b Instituto de Investigación Sanitaria de Navarra   (Spain)

^c HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

Author keywords

Critical patient; Impact of nosocomial infection; Nosocomial infection; Surveillance

Indexed keywords

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; BACTERIUM CULTURE; BLOODSTREAM INFECTION; CANDIDA ALBICANS; CRITICALLY ILL PATIENT; DISEASE SEVERITY; ENTEROCOCCUS FAECALIS; ESCHERICHIA COLI; HOSPITAL INFECTION; HUMAN; INCIDENCE; INTENSIVE CARE UNIT; KLEBSIELLA PNEUMONIAE; MEDICAL LITERATURE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTIDRUG RESISTANCE; PREVALENCE; PSEUDOMONAS AERUGINOSA; SHORT SURVEY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; URINARY TRACT INFECTION; VENTILATOR ASSOCIATED PNEUMONIA;

CROSS INFECTION; HUMANS;

EID: 77952888714     PISSN: 02105691     EISSN: 15786749     Source Type: Journal    
DOI: 10.1016/j.medin.2009.11.013     Document Type: Short Survey

References (101)

1. Fauci A.S., Touchette N.A., Folkers G.K. Emerging infectious diseases: A 10-year perspective from the National Institute of Allergy and Infectious Diseases. Emerg Infect Dis 2005, 11:519-525.
2. Biedenbach D.J., Moet G.J., Jones R.N. Occurrence and antimicrobial resistance pattern comparisons among bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (1997-2002). Diagn Microbiol Infect Dis 2004, 50:59-69.
3. Klevens R.M., Morrison M.A., Nadle J., Petit S., Gershman K., Ray S., et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 2007, 298:1763-1771.
4. Barcenilla F, Jover A, Castellana D, López R. Control de la infección nosocomial. Una visión más allá de cuidados intensivos. En: Net A, Quintana E, editores. Infecciones en Medicina Intensiva. Barcelona: Ars Medica; 2007. p. 19-28.
5. Haley R.W., Culver D.H., White J.W., Morgan W.M., Emori T.G. The nationwide nosocomial infection rate. A new need for vital statistics. Am J Epidemiol 1985, 121:159-167.
6. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004;32:470-85.
7. Suetens C., Morales I., Savey A., Palomar M., Hiesmayr M., Lepape A., et al. European surveillance of ICU-acquired infections (HELICS-ICU): Methods and main results. J Hosp Infect 2007, 65:171-173.
8. Gastmeier P., Sohr D., Schwab F., Behnke M., Zuschneid I., Brandt C., et al. Ten years of KISS: The most important requirements for success. J Hosp Infect 2008, 70:11-16.
9. Mannien J., van den H.S., Muilwijk J., van den Broek P.J., van Benthem B., Wille J.C. Trends in the incidence of surgical site infection in the Netherlands. Infect Control Hosp Epidemiol 2008, 29:1132-1138.
10. Astagneau P., L'Heriteau F., Daniel F., Parneix P., Venier A.G., Malavaud S., et al. Reducing surgical site infection incidence through a network: Results from the French ISO-RAISIN surveillance system. J Hosp Infect 2009, 72:127-134.
11. Rosenthal V.D., Maki D.G., Graves N. The International Nosocomial Infection Control Consortium (INICC): Goals and objectives, description of surveillance methods, and operational activities. Am J Infect Control 2008, 36:1-12.
12. Rossello-Urgell J., Vaque-Rafart J., Villate-Navarro J.I., Sánchez-Paya J., Martínez-Gómez X., Arribas-Llorente J.L., et al. Exposure to extrinsic risk factors in prevalence surveys of hospital-acquired infections: A methodological approach. J Hosp Infect 2006, 62:366-371.
13. Álvarez-Lerma F., Palomar M., Olaechea P., Otal J.J., Insausti J., Cerda E. Estudio Nacional de Vigilancia de Infección Nosocomial en Unidades de Cuidados Intensivos. Informe evolutivo de los años 2003-2005. Med Intensiva 2007, 31:6-17.
14. Martin M.C., Cabre L., Ruiz J., Blanch L., Blanco J., Castillo F., et al. Indicadores de calidad en el paciente crítico. Med Intensiva 2008, 32:23-32.
15. Sánchez A, Palomar M, Alcaraz R, Moreira D. Infección nosocomial en unidad de cuidados intensivos " 0": ¿un objetivo alcanzable para todas las unidades? En: Net A y Quintana E, editores. Infecciones en Medicina Intensiva. Barcelona: Ars Medica; 2007. p. 1-17. ISBN 978-84-9751-274-9.
16. Insausti J., Palomar M., Álvarez F., Otal J.J., Olaechea P., López M.J., et al. Estudio nacional de vigilancia de infección nosocomial en UCI. Informe del año 2008. Med Intensiva 2009, 33:109.
17. Fridkin S.K., Hageman J.C., Morrison M., Sanza L.T., Como-Sabetti K., Jeringan J.A., et al. Methicillin-resistant Staphylococcus aureus disease in three communities. N Engl J Med 2005, 352:1436-1444.
18. Cercenado E., Cuevas O., Marin M., Bouza E., Trincado P., Boquete T., et al. Community-acquired methicillin-resistant Staphylococcus aureus in Madrid, Spain: Transcontinental importation and polyclonal emergence of Panton-Valentine leukocidin-positive isolates. Diagn Microbiol Infect Dis 2008, 61:143-149.
19. Oteo J., Cuevas O., Navarro C., Aracil B., Campos J. Trends in antimicrobial resistance in 3469 enterococci isolated from blood (EARSS experience 2001-06, Spain): Increasing ampicillin resistance in Enterococcus faecium. J Antimicrob Chemother 2007, 59:1044-1045.
20. Maciá M.D., Juan C., Oliver A., Hidalgo O., Pérez J.L. Caracterización molecular de un brote por Enterococcus faecalis resistente a los glucopéptidos en una unidad de cuidados intensivos. Enferm Infecc Microbiol Clin 2005, 23:460-463.
21. Vincent J.L., Brun-Buisson C., Niederman M., Haenni C., Harbarth S., Sprumont D., et al. Ethics roundtable debate: A patient dies from an ICU-acquired infection related to methicillin-resistant Staphylococcus aureus-how do you defend your case and your team?. Crit Care 2005, 9:5-9.
22. Bryan C.S., Call T.J., Elliott K.C. The ethics of infection control: Philosophical frameworks. Infect Control Hosp Epidemiol 2007, 28:1077-1084.
23. Haley R.W., Schaberg D.R., Crossley K.B., Von Allmen S.D., McGowan J.E. Extra charges and prolongation of stay attributable to nosocomial infections: A prospective interhospital comparison. Am J Med 1981, 70:51-58.
24. Wakefield D.S., Pfaller M., Ludke R.L., Wenzel R.P. Methods for estimating days of hospitalization due to nosocomial infections. Med Care 1992, 30:373-376.
25. Delgado-Rodríguez M., Medina-Cuadros M., Bueno-Cavanillas A., Martínez-Gallego G., Dierssen T., Sillero-Arenas M. Comparison of two procedures to estimate the hospital stay attributable to nosocomial infection: Matched cohort study versus analysis of covariance of the total unmatched cohort. J Clin Epidemiol 1997, 50:773-778.
26. Blot S., Depuydt P., Vandewoude K., De Bacquer D. Measuring the impact of multidrug resistance in nosocomial infection. Curr Opin Infect Dis 2007, 20:391-396.
27. Fabbro-Peray P., Sotto A., Defez C., Cazaban M., Molinari L., Pinede M., et al. Mortality attributable to nosocomial infection: A cohort of patients with and without nosocomial infection in a French university hospital. Infect Control Hosp Epidemiol 2007, 28:265-272.
28. Blot S. Limiting the attributable mortality of nosocomial infection and multidrug resistance in intensive care units. Clin Microbiol Infect 2008, 14:5-13.
29. Garnacho-Montero J., Ortiz-Leyba C., Herrera-Melero I., Aldabo-Pallas T., Cayuela-Domínguez A., Márquez-Vacaro J.A., et al. Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: A matched cohort study. J Antimicrob Chemother 2008, 61:436-441.
30. Sostarich A.M., Zolldann D., Haefner H., Luetticken R., Schulze-Roebecke R., Lemmen S.W. Impact of multiresistance of gram-negative bacteria in bloodstream infection on mortality rates and length of stay. Infection 2008, 36:31-35.
31. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42:S82-S89.
32. McGregor J.C., Rich S.E., Harris A.D., Perencevich E.N., Osih R., Lodise T.P., et al. A systematic review of the methods used to assess the association between appropriate antibiotic therapy and mortality in bacteremic patients. Clin Infect Dis 2007, 45:329-337.
33. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
34. Harbarth S., Nobre V., Pittet D. Does antibiotic selection impact patient outcome?. Clin Infect Dis 2007, 44:87-93.
35. Zaragoza R., Artero A., Camarena J.J., Sancho S., González R., Nogueira J.M. The influence of inadequate empirical antimicrobial treatment on patients with bloodstream infections in an intensive care unit. Clin Microbiol Infect 2003, 9:412-418.
36. Osih R.B., McGregor J.C., Rich S.E., Moore A.C., Furuno J., Perencevich E.N., et al. Impact of empiric antibiotic therapy on outcomes in patients with Pseudomonas aeruginosa bacteremia. Antimicrob Agents Chemother 2007, 51:839-844.
37. Fagon J.Y., Novara A., Stephan F., Girou E., Safar M. Mortality attributable to nosocomial infections in the ICU. Infect Control Hosp Epidemiol 1994, 15:428-434.
38. Salomao R., Rosenthal V.D., Grimberg G., Coger S., Blecher S., Buchner-Ferreira S., et al. Device-associated infection rates in intensive care units of Brazilian hospitals: Findings of the International Nosocomial Infection Control Consortium. Rev Panam Salud Publica 2008, 24:195-202.
39. Cuellar L.E., Fernández-Maldonado E., Rosenthal V.D., Castaneda-Sabogal A., Rosales R., Mayorga-Espichan M.J., et al. Device-associated infection rates and mortality in intensive care units of Peruvian hospitals: Findings of the International Nosocomial Infection Control Consortium. Rev Panam Salud Publica 2008, 24:16-24.
40. Muscedere J.G., Martin C.M., Heyland D.K. The impact of ventilator-associated pneumonia on the Canadian health care system. J Crit Care 2008, 23:5-10.
41. Valles J., Pobo A., García-Esquirol O., Mariscal D., Real J., Fernández R. Excess ICU mortality attributable to ventilator-associated pneumonia: The role of early vs late onset. Intensive Care Med 2007, 33:1363-1368.
42. Fagon J.Y., Chastre J., Hance A.J., Montravers P., Novara A., Gibert C. Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. Am J Med 1993, 94:281-288.
43. Rello J., Ollendorf D.A., Oster G., Vera-Llonch M., Bellm L., Redman R., et al. Epidemiology and outcomes of ventilator-associated pneumonia in a large US database. Chest 2002, 122:2115-2121.
44. Moine P., Timsit J.F., De Lassence A., Troche G., Fosse J.P., Alberti C., et al. Mortality associated with late-onset pneumonia in the intensive care unit: Results of a multi-center cohort study. Intensive Care Med 2002, 28:154-163.
45. Leroy O., Meybeck A., D'Escrivan T., Devos P., Kipnis E., Georges H. Impact of adequacy of initial antimicrobial therapy on the prognosis of patients with ventilator-associated pneumonia. Intensive Care Med 2003, 29:2170-2173.
46. Álvarez-Lerma F. Modification of empiric antibiotic treatment in patients with pneumonia acquired in the intensive care unit. ICU-Acquired Pneumonia Study Group. Intensive Care Med 1996, 22:387-394.
47. Kollef M.H., Silver P., Murphy D.M., Trovillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest 1995, 108:1655-1662.
48. Kollef M.H., Sherman G., Ward S., Fraser V.J. Inadequate antimicrobial treatment of infections: A risk factor for hospital mortality among critically ill patients. Chest 1999, 115:462-474.
49. Heyland D.K., Cook D.J., Griffith L., Keenan S.P., Brun-Buisson C. The attributable morbidity and mortality of ventilator-associated pneumonia in the critically ill patient. The Canadian Critical Trials Group. Am J Respir Crit Care Med 1999, 159:1249-1256.
50. Renaud B., Brun-Buisson C. Outcomes of primary and catheter-related bacteremia. A cohort and case-control study in critically ill patients. Am J Respir Crit Care Med 2001, 163:1584-1590.
51. Girou E., Stephan F., Novara A., Safar M., Fagon J.Y. Risk factors and outcome of nosocomial infections: Results of a matched case-control study of ICU patients. Am J Respir Crit Care Med 1998, 157:1151-1158.
52. Pittet D., Tarara D., Wenzel R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994, 271:1598-1601.
53. Di Giovine B., Chenoweth C., Watts C., Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999, 160:976-981.
54. Rello J., Ochagavia A., Sabanes E., Roque M., Mariscal D., Reynaga E., et al. Evaluation of outcome of intravenous catheter-related infections in critically ill patients. Am J Respir Crit Care Med 2000, 162:1027-1030.
55. Garrouste-Orgeas M., Timsit J.F., Tafflet M., Misset B., Zahar J.R., Soufir L., et al. Excess risk of death from intensive care unit-acquired nosocomial bloodstream infections: A reappraisal. Clin Infect Dis 2006, 42:1118-1126.
56. Olaechea P.M., Álvarez-Lerma F., Palomar M., Otal J.J., Insausti J., López Pueyo M.J., et al. Mortalidad asociada a la bacteriemia primaria y relacionada con catéter. Estudio de cohortes emparejado. ENVIN-UCI 1997-2007. Med Intensiva 2009, 33:109.
57. Bagshaw S.M., Laupland K.B. Epidemiology of intensive care unit-acquired urinary tract infections. Curr Opin Infect Dis 2006, 19:67-71.
58. Clec'h C., Schwebel C., Francais A., Toledano D., Fosse J P., Garrouste-Orgeas M., et al. Does catheter-associated urinary tract infection increase mortality in critically ill patients?. Infect Control Hosp Epidemiol 2007, 28:1367-1373.
59. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: A meta-analysis. Clin Infect Dis 2003, 36:53-59.
60. Cosgrove S.E., Qi Y., Kaye K.S., Harbarth S., Karchmer A.W., Carmeli Y. The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: Mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005, 26:166-174.
61. Blot S.I., Vandewoude K.H., Hoste E.A., Colardyn F.A. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med 2002, 162:2229-2235.
62. Zahar J.R., Clec'h C., Tafflet M., Garrouste-Orgeas M., Jamali S., Mourvillier B., et al. Is methicillin resistance associated with a worse prognosis in Staphylococcus aureus ventilator-associated pneumonia?. Clin Infect Dis 2005, 41:1224-1231.
63. Soriano A., Martinez J.A., Mensa J., Marco F., Almela M., Moreno-Martínez A., et al. Pathogenic significance of methicillin resistance for patients with Staphylococcus aureus bacteremia. Clin Infect Dis 2000, 30:368-373.
64. Combes A., Luyt C.E., Fagon J.Y., Wolff M., Trouillet J.L., Chastre J. Impact of methicillin resistance on outcome of Staphylococcus aureus ventilator-associated pneumonia. Am J Respir Crit Care Med 2004, 170:786-792.
65. Rello J., Sole-Violan J., Sa-Borges M., Garnacho-Montero J., Muñoz E., Sirgo G., et al. Pneumonia caused by oxacillin-resistant Staphylococcus aureus treated with glycopeptides. Crit Care Med 2005, 33:1983-1987.
66. Schramm G.E., Johnson J.A., Doherty J.A., Micek S.T., Kollef M.H. Methicillin-resistant Staphylococcus aureus sterile-site infection: The importance of appropriate initial antimicrobial treatment. Crit Care Med 2006, 34:2069-2074.
67. Lodise T.P., McKinnon P.S. Burden of methicillin-resistant Staphylococcus aureus: Focus on clinical and economic outcomes. Pharmacotherapy 2007, 27:1001-1012.
68. Shurland S., Zhan M., Bradham D.D., Roghmann M.C. Comparison of mortality risk associated with bacteremia due to methicillin-resistant and methicillin-susceptible Staphylococcus aureus. Infect Control Hosp Epidemiol 2007, 28:273-279.
69. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Risk factors for antimicrobial resistance and influence of resistance on mortality in patients with bloodstream infection caused by Pseudomonas aeruginosa. Microb Drug Resist 2005, 11:68-74.
70. Lautenbach E., Weiner M.G., Nachamkin I., Bilker W.B., Sheridan A., Fishman N.O. Imipenem resistance among Pseudomonas aeruginosa isolates: Risk factors for infection and impact of resistance on clinical and economic outcomes. Infect Control Hosp Epidemiol 2006, 27:893-900.
71. Combes A., Luyt C.E., Fagon J.Y., Wolff M., Trouillet J.L., Chastre J. Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia. Intensive Care Med 2006, 32:1970-1978.
72. Trouillet J.L., Vuagnat A., Combes A., Kassis N., Chastre J., Gibert C. Pseudomonas aeruginosa ventilator-associated pneumonia: Comparison of episodes due to piperacillin-resistant versus piperacillin-susceptible organisms. Clin Infect Dis 2002, 34:1047-1054.
73. Ibrahim E.H., Sherman G., Ward S., Fraser V.J., Kollef M.H. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000, 118:146-155.
74. Carmeli Y., Troillet N., Karchmer A.W., Samore M.H. Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999, 159:1127-1132.
75. Abbo A., Carmeli Y., Navon-Venezia S., Siegman-Igra Y., Schwaber M.J. Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes. Eur J Clin Microbiol Infect Dis 2007, 26:793-800.
76. Grupper M., Sprecher H., Mashiach T., Finkelstein R. Attributable mortality of nosocomial Acinetobacter bacteremia. Infect Control Hosp Epidemiol 2007, 28:293-298.
77. Playford E.G., Craig J.C., Iredell J.R. Carbapenem-resistant Acinetobacter baumannii in intensive care unit patients: Risk factors for acquisition, infection and their consequences. J Hosp Infect 2007, 65:204-211.
78. Lee N.Y., Lee H.C., Ko N.Y., Chang C.M., Shih H.I., Wu C.J., et al. Clinical and economic impact of multidrug resistance in nosocomial Acinetobacter baumannii bacteremia. Infect Control Hosp Epidemiol 2007, 28:713-719.
79. Kollef K.E., Schramm G.E., Wills A.R., Reichley R.M., Micek S.T., Kollef M.H. Predictors of 30-day mortality and hospital costs in patients with ventilator-associated pneumonia attributed to potentially antibiotic-resistant gram-negative bacteria. Chest 2008, 134:281-287.
80. Blot S., Vandewoude K., Colardyn F. Nosocomial bacteremia involving Acinetobacter baumannii in critically ill patients: A matched cohort study. Intensive Care Med 2003, 29:471-475.
81. Garnacho-Montero J., Ortiz-Leyba C., Fernández-Hinojosa E., Aldabo-Pallas T., Cayuela A., Márquez-Vacaro J.A., et al. Acinetobacter baumannii ventilator-associated pneumonia: Epidemiological and clinical findings. Intensive Care Med 2005, 31:649-655.
82. Garnacho J., Sole-Violan J., Sa-Borges M., Díaz E., Rello J. Clinical impact of pneumonia caused by Acinetobacter baumannii in intubated patients: A matched cohort study. Crit Care Med 2003, 31:2478-2482.
83. Melzer M., Petersen I. Mortality following bacteraemic infection caused by extended spectrum beta-lactamase (ESBL) producing E. coli compared to non-ESBL producing E. coli. J Infect 2007, 55:254-259.
84. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: Variability by site of infection. Arch Intern Med 2005, 165:1375-1380.
85. Tumbarello M., Sali M., Trecarichi E.M., Leone F., Rossi M., Fiori B., et al. Bloodstream infections caused by extended-spectrum beta-lactamase-producing Escherichia coli: Risk factors for inadequate initial antimicrobial therapy. Antimicrob Agents Chemother 2008, 52:3244-3252.
86. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581.
87. Pena C., Gudiol C., Calatayud L., Tubau F., Domínguez M.A., Pujol M., et al. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: Factors influencing mortality. J Hosp Infect 2008, 68:116-122.
88. Kola A., Maciejewski O., Sohr D., Ziesing S., Gastmeier P. Clinical impact of infections caused by ESBL-producing E. coli and K. pneumoniae. Scand J Infect Dis 2007, 39:975-982.
89. Schwaber M.J., Carmeli Y. Mortality and delay in effective therapy associated with extended-spectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 2007, 60:913-920.
90. Olaechea P.M., Ulibarrena M.A., Álvarez-Lerma F., Insausti J., Palomar M., De la Cal M.A. Factors related to hospital stay among patients with nosocomial infection acquired in the intensive care unit. Infect Control Hosp Epidemiol 2003, 24:207-213.
91. DiGiovine B., Chenoweth C., Watts C., Higgins M. The attributable mortality and costs of primary nosocomial bloodstream infections in the intensive care unit. Am J Respir Crit Care Med 1999, 160:976-981.
92. Pittet D., Tarara D., Wenzel R.P. Nosocomial bloodstream infection in critically ill patients. Excess length of stay, extra costs, and attributable mortality. JAMA 1994, 271:1598-1601.
93. Kirkland K.B., Weinstein J.M. Adverse effects of contact isolation. Lancet 1999, 354:1177-1178.
94. Stelfox H.T., Bates D.W., Redelmeier D.A. Safety of patients isolated for infection control. JAMA 2003, 290:1899-1905.
95. Olaechea P.M., Palomar M., León-Gil C., Álvarez-Lerma F., Jorda R., Nolla-Salas J., et al. Economic impact of Candida colonization and Candida infection in the critically ill patient. Eur J Clin Microbiol Infect Dis 2004, 23:323-330.
96. Bantar C., Sartori B., Vesco E., Heft C., Saul M., Salamote F., et al. A hospitalwide intervention program to optimize the quality of antibiotic use: Impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003, 37:180-186.
97. Cosgrove S.E. The relationship between antimicrobial resistance and patient outcomes: Mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006, 42:S82-S89.
98. Kilgore M.L., Ghosh K., Beavers C.M., Wong D.Y., Hymel P.A., Brossette S.E. The costs of nosocomial infections. Med Care 2008, 46:101-104.
99. Sánchez-Velázquez L.D., Ponce de León R.S., Rangel Frausto M.S. The burden of nosocomial infection in the intensive care unit: Effects on organ failure, mortality and costs. A nested case-control study. Arch Med Res 2006, 37:370-375.
100. Lee S.Y., Kotapati S., Kuti J.L., Nightingale C.H., Nicolau D.P. Impact of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: A matched cohort study. Infect Control Hosp Epidemiol 2006, 27:1226-1232.
101. Jain M., Miller L., Belt D., King D., Berwick D.M. Decline in ICU adverse events, nosocomial infections and cost through a quality improvement initiative focusing on teamwork and culture change. Qual Saf Health Care 2006, 15:235-239.